Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 3.73
ENZ's Cash to Debt is ranked higher than
74% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. ENZ: 3.73 )
ENZ' s 10-Year Cash to Debt Range
Min: 1.91   Max: No Debt
Current: 3.73

Equity to Asset 0.59
ENZ's Equity to Asset is ranked higher than
71% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. ENZ: 0.59 )
ENZ' s 10-Year Equity to Asset Range
Min: 0.57   Max: 0.97
Current: 0.59

0.57
0.97
F-Score: 6
Z-Score: -2.35
M-Score: -3.12
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -10.92
ENZ's Operating margin (%) is ranked higher than
66% of the 249 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.55 vs. ENZ: -10.92 )
ENZ' s 10-Year Operating margin (%) Range
Min: -50.6   Max: 16.64
Current: -10.92

-50.6
16.64
Net-margin (%) -11.82
ENZ's Net-margin (%) is ranked higher than
66% of the 249 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.38 vs. ENZ: -11.82 )
ENZ' s 10-Year Net-margin (%) Range
Min: -39.34   Max: 17.67
Current: -11.82

-39.34
17.67
ROE (%) -32.14
ENZ's ROE (%) is ranked higher than
61% of the 233 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.03 vs. ENZ: -32.14 )
ENZ' s 10-Year ROE (%) Range
Min: -56.99   Max: 9
Current: -32.14

-56.99
9
ROA (%) -18.77
ENZ's ROA (%) is ranked higher than
63% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.48 vs. ENZ: -18.77 )
ENZ' s 10-Year ROA (%) Range
Min: -43.97   Max: 8.6
Current: -18.77

-43.97
8.6
ROC (Joel Greenblatt) (%) -100.90
ENZ's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. ENZ: -100.90 )
ENZ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -228.6   Max: 33.58
Current: -100.9

-228.6
33.58
Revenue Growth (3Y)(%) -5.40
ENZ's Revenue Growth (3Y)(%) is ranked higher than
63% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. ENZ: -5.40 )
ENZ' s 10-Year Revenue Growth (3Y)(%) Range
Min: -9.9   Max: 24.4
Current: -5.4

-9.9
24.4
EBITDA Growth (3Y)(%) -16.10
ENZ's EBITDA Growth (3Y)(%) is ranked higher than
61% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. ENZ: -16.10 )
ENZ' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 157.1
Current: -16.1

0
157.1
EPS Growth (3Y)(%) -12.20
ENZ's EPS Growth (3Y)(%) is ranked higher than
65% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. ENZ: -12.20 )
ENZ' s 10-Year EPS Growth (3Y)(%) Range
Min: -24.6   Max: 58.7
Current: -12.2

-24.6
58.7
» ENZ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ENZ Guru Trades in Q1 2014

Jim Simons 447,881 sh (+29.58%)
» More
Q2 2014

ENZ Guru Trades in Q2 2014

Jim Simons 563,818 sh (+25.89%)
» More
Q3 2014

ENZ Guru Trades in Q3 2014

Dodge & Cox 15,570 sh (New)
Jim Simons 928,800 sh (+64.73%)
» More
Q4 2014

ENZ Guru Trades in Q4 2014

Jim Simons 944,337 sh (+1.67%)
Dodge & Cox Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ENZ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.74
ENZ's P/B is ranked higher than
72% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.82 vs. ENZ: 3.74 )
ENZ' s 10-Year P/B Range
Min: 0.85   Max: 7.13
Current: 3.74

0.85
7.13
P/S 1.32
ENZ's P/S is ranked higher than
91% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.63 vs. ENZ: 1.32 )
ENZ' s 10-Year P/S Range
Min: 0.56   Max: 15.23
Current: 1.32

0.56
15.23
Current Ratio 1.63
ENZ's Current Ratio is ranked higher than
59% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. ENZ: 1.63 )
ENZ' s 10-Year Current Ratio Range
Min: 1.34   Max: 33.9
Current: 1.63

1.34
33.9
Quick Ratio 1.27
ENZ's Quick Ratio is ranked higher than
56% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. ENZ: 1.27 )
ENZ' s 10-Year Quick Ratio Range
Min: 0.95   Max: 33.15
Current: 1.27

0.95
33.15
Days Inventory 58.58
ENZ's Days Inventory is ranked higher than
82% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 131.99 vs. ENZ: 58.58 )
ENZ' s 10-Year Days Inventory Range
Min: 35.73   Max: 117.91
Current: 58.58

35.73
117.91
Days Sales Outstanding 44.47
ENZ's Days Sales Outstanding is ranked higher than
88% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 74.31 vs. ENZ: 44.47 )
ENZ' s 10-Year Days Sales Outstanding Range
Min: 47.44   Max: 177.79
Current: 44.47

47.44
177.79

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 10.67
ENZ's Price/Net Current Asset Value is ranked higher than
82% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ENZ: 10.67 )
ENZ' s 10-Year Price/Net Current Asset Value Range
Min: 2.37   Max: 33.58
Current: 10.67

2.37
33.58
Price/Tangible Book 6.40
ENZ's Price/Tangible Book is ranked higher than
72% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.60 vs. ENZ: 6.40 )
ENZ' s 10-Year Price/Tangible Book Range
Min: 1.97   Max: 29.77
Current: 6.4

1.97
29.77
Price/Median PS Value 0.58
ENZ's Price/Median PS Value is ranked higher than
95% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. ENZ: 0.58 )
ENZ' s 10-Year Price/Median PS Value Range
Min: 0.25   Max: 21.21
Current: 0.58

0.25
21.21
Earnings Yield (Greenblatt) -8.90
ENZ's Earnings Yield (Greenblatt) is ranked higher than
58% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. ENZ: -8.90 )
ENZ' s 10-Year Earnings Yield (Greenblatt) Range
Min: -10.1   Max: 0
Current: -8.9

-10.1
0
Forward Rate of Return (Yacktman) 8.07
ENZ's Forward Rate of Return (Yacktman) is ranked higher than
69% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.73 vs. ENZ: 8.07 )
ENZ' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -31.2   Max: 16.7
Current: 8.07

-31.2
16.7

Analyst Estimate

Jul15
Revenue(Mil) 102
EPS($) -0.23
EPS without NRI($) -0.23

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, IDXX » details
Traded in other countries:EZB.Germany,
Enzo Biochem Inc was founded in 1976. It is engaged in research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally. The Company is conducting research and development activities in the development of therapeutic products based on the Companys technology platform of genetic modulation and immune modulation. The Company also operates a clinical laboratory that offers and provides diagnostic medical testing services to the health care community in the New York Metropolitan and New Jersey areas. The Company operates in three segments of which the Therapeutics and Life Sciences segments have evolved out of its core competencies. enzo Life Sciences manufactures, develops and markets functional biology and cellular biochemistry products and tools to research and pharmaceutical customers world-wide and has amassed a large patent and technology portfolio, enzo Clinical Labs is a regional clinical laboratory serving the New York Metropolitan and New Jersey areas, enzo Therapeutics is a biopharmaceutical venture that has developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of enzo Life Sciences. The Company has developed a portfolio of proprietary technologies with research, diagnostic and therapeutic applications. It is applying its core technologies to develop novel therapeutics as well as research tools for the life sciences and clinical diagnostics markets. In addition, The Company provides clinical laboratory services to physicians and other health care providers in the New York Metropolitan and New Jersey area. The Company is organized to the development, production, marketing and sales of life science research reagents. The products supplied by Enzo Life Sciences include small molecules, proteins, antibodies, peptides, assay kits and custom services. Enzo Life Sciences is organized to promote and market its product through its seven brands Enzo, Alexis, Apotech, Axxora, Biomol, Assay Designs and Stressgen. Therapeutic Development Programs include Autoimmune Uveitis, Inflammatory bowel diseases. Osteoporosis (and certain bone disorders) and Diabetes, Non-Alcoholic SteatoHepatitis (NASH) and Human Immunodeficiency Virus (HIV-1). The Company competes with other life science and biotechnology companies, as well as pharmaceutical, chemical and other companies. The clinical laboratory industry is subject to federal and state regulation, including inspections and audits by governmental agencies.
» More Articles for ENZ

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BWEN, DDMG, ZHNE, ENZ, SIRO Nov 28 2011 
Weekly CFO Buys Highlight: BWEN, ENZ, PIP, HAFC, AACC Nov 21 2011 
Enzo Biochem Inc. Reports Operating Results (10-Q) Mar 14 2011 
Enzo Biochem Inc. Reports Operating Results (10-Q) Dec 10 2010 
Enzo Biochem Inc. Reports Operating Results (10-Q) Jun 09 2010 
Enzo Biochem Inc. Reports Operating Results (10-Q) Dec 10 2009 
Weekly Top Insider Buys: Bank of America Corp., Safeway Inc., Umpqua Holdings Corp., National Penn B Oct 25 2009 
Weekly Top Insider Buys: KB Home, National Penn Bancshares Inc., Moduslink Global Solutions Inc., En Oct 20 2009 
Enzo Biochem Inc. Reports Operating Results (10-Q) Sep 04 2009 
Enzo Biochem Inc. (ENZ) Files Quarterly Report for the Period Ended on 2008-10-31 Dec 15 2008 

More From Other Websites
ENZO Biochem to Request Rehearing of Court of Appeals Decision Mar 27 2015
ENZO Biochem Announces New York State Approval of First Flowscript™ Assay For Improved Detection... Mar 27 2015
ENZO Biochem Reports Fiscal Second Quarter Results March 12, 2015 Mar 27 2015
ENZO Biochem Schedules Teleconference to Discuss Second Quarter Results Friday, March 13, 2015 at... Mar 27 2015
ENZO BIOCHEM INC Financials Mar 19 2015
Enzo, StingRay, Tenax, CloudFlare: Intellectual Property Mar 16 2015
ENZO BIOCHEM INC Files SEC form 8-K, Other Events Mar 16 2015
Enzo Plunges After $61 Million Applera Judgment Tossed Mar 16 2015
Enzo Biochem to Request Rehearing of Court of Appeals Decision Mar 16 2015
ENZO BIOCHEM INC Files SEC form 8-K, Other Events Mar 13 2015
Enzo Biochem Announces New York State Approval of First FlowScript™ Assay for Improved Detection... Mar 13 2015
ENZO BIOCHEM INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Mar 12 2015
Enzo Biochem Reports Fiscal Second Quarter Results Mar 12 2015
Q2 2015 Enzo Biochem Inc Earnings Release - After Market Close Mar 12 2015
Enzo Biochem Schedules Teleconference to Discuss Second Quarter Results Friday, March 13, 2015 at... Mar 09 2015
Enzo Biochem (ENZ) Looks Good: Stock Moves 14.8% Higher - Tale of the Tape Feb 25 2015
ENZO BIOCHEM INC Files SEC form 8-K, Other Events Feb 10 2015
Enzo Biochem Announces New Molecular Platform and First Product for Early Focus on Cervical Cancer... Feb 10 2015
ENZO BIOCHEM INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jan 23 2015
ENZO BIOCHEM INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Dec 31 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK